Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent

- January 18th, 2018

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has entered a Notice of Allowance for U.S. Patent Application 15/088,539 covering the use of RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor … Continued

Strongbridge Biopharma (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has entered a Notice of Allowance for U.S. Patent Application 15/088,539 covering the use of RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing’s syndrome.
As quoted in the press release:

“The patent scheduled to issue from this application should result in additional intellectual property protection for RECORLEV, potentially extending our drug candidate’s patent term beyond orphan drug exclusivity and enhancing the overall RECORLEV patent portfolio,” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma. “This marks an important step in our ongoing efforts to optimize the value of RECORLEV and further strengthens Strongbridge’s leadership position in rare endocrine disease,” Pauls added.

Click here to read the full press release.

Is it a good time to buy gold stocks?


Learn to profit from gold's low price this year!


Give me my free report!

Leave a Reply

Your email address will not be published. Required fields are marked *